F-1: Evogene Seeks to Register Resale of 3.38 Million Shares Underlying Warrants

Evogene Ltd. files for registration to allow a selling shareholder to resell up to 3,384,616 ordinary shares underlying warrants acquired in a private placement.

Summary

• Evogene Ltd. has filed a registration statement for the resale of up to 3,384,616 ordinary shares by a selling shareholder.
• These shares are issuable upon the exercise of ordinary warrants, which include 1,692,308 Series A warrants and 1,692,308 Series B warrants.
• The warrants were sold in a private placement completed on August 26, 2024, under a securities purchase agreement dated August 23, 2024.
• Both Series A and Series B warrants have an exercise price of $3.55 per share and were immediately exercisable upon issuance.
• The Series A warrants expire five years from issuance (August 26, 2029), while the Series B warrants expire eighteen months from issuance (February 26, 2026).
• Evogene will not receive any proceeds from the sale of ordinary shares by the selling shareholder, but could receive up to approximately $12.02 million in cash if all warrants are exercised.
• As of September 17, 2024, Evogene's ordinary shares traded on the Nasdaq Capital Market under the symbol EVGN at a price of $2.84 per share.
• The company emphasizes that investing in its ordinary shares is highly speculative and involves a high degree of risk.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments like revenue growth and reduced net losses, the emphasis on investment risks and potential dilution tempers the overall outlook. The delays in Casterra's orders and the need for additional capital further contribute to a neutral sentiment.

Positives

• Revenue increased to approximately $914,000 and $5.1 million in the second quarter and first half of 2024, respectively.
• Net loss decreased to approximately $6.0 million and $9.8 million for the second quarter and first half of 2024, respectively.
• Casterra announced it will be receiving a $440,000 purchase order to supply castor seeds to a new African country in 2024.
• Biomica successfully completed Phase I trial enrollment for a microbiome-based immuno-oncology drug.
• Lavie Bio successfully completed testing of Yalos for winter wheat and will commence sales across the United States for the 2024-2025 season.
• Lavie Bio announced a significant milestone in its collaboration with ICL Group Ltd. to develop bio-stimulant solutions for key row crops facing extreme weather conditions by leveraging AI to identify over a dozen novel microbes within 12 months.
• AgPlenus announced a licensing and collaboration agreement with Bayer AG to develop a new sustainable weed control solution.

Negatives

• Investing in Evogene's ordinary shares is highly speculative and involves a high degree of risk.
• Casterra has experienced delays in supplying certain of its orders, which may reduce previously anticipated revenues.
• The company has a history of operating losses and negative cash flow.
• The company needs substantial additional capital in the future, which may cause dilution to existing shareholders.
• Dilution of equity holdings in subsidiary companies will likely negatively impact results of operations.
• Discoveries and product candidates may not achieve the desired effect required in order to create commercially viable products.
• Research and development milestones and the commercialization of product candidates may be delayed or not achieved.
• The company relies on a limited number of collaborators to develop and commercialize product candidates.
• Competition in the industries is intense and requires continuous technological development.
• Growing cycles and adverse weather conditions may decrease results from operations.
• The company may not be able to protect intellectual property rights throughout the world.
• Third-party seed growers in Africa and Brazil may not deliver seeds on time to Casterra.
• The ongoing war and other conditions in Israel, where most of operations are conducted, may adversely affect operations.

Risks

• The company has a history of operating losses and may never achieve or maintain profitability.
• The company needs substantial additional capital, which could dilute existing shareholders and restrict operations.
• Discoveries and product candidates may not achieve commercial viability.
• Research and development and commercialization may be delayed or not achieved.
• The company relies on a limited number of collaborators.
• Competition is intense and requires continuous technological development.
• Growing cycles and adverse weather conditions may decrease results.
• The company may not be able to protect intellectual property rights.
• Third-party seed growers may not deliver seeds on time.
• The ongoing war and other conditions in Israel may adversely affect operations.
• Casterra has experienced delays in supplying certain of its orders, which may reduce previously anticipated revenues from Casterra.
• Shareholders may experience significant dilution as a result of financings and potential future financings that may be effected.
• An active trading market for the ordinary shares may not be sustained.
• The share price may be subject to substantial volatility, and shareholders may lose all or a substantial part of their investment.
• Nasdaq may delist the ordinary shares from its exchange which could limit the ability to make transactions in the securities and subject the company to additional trading restrictions.

Future Outlook

The company plans to maintain its research and development focus on MicroBoost AI and ChemPass AI. Lavie Bio's pipeline is advancing according to plan, with field trials initiated in the second quarter of 2024 in most of the company's programs, and results expected during the fourth quarter of 2024.

Industry Context

Evogene operates in the computational biology sector, aiming to revolutionize life-science product development across human health, agriculture, and other industries. The company's subsidiaries focus on microbiome-based therapeutics, ag-chemicals, ag-biologicals, and castor seeds for bio-based industrial applications. The document mentions collaborations with Bayer AG and ICL Group Ltd., indicating a strategy of partnering with established players in the agriculture and chemical industries.

Comparison to Industry Standards

• It's difficult to provide a precise comparison to industry standards without specific financial benchmarks for computational biology companies of similar size and focus.
• However, companies like Recursion Pharmaceuticals and Schrodinger are also leveraging computational methods in drug discovery, and their financial performance and market capitalization could provide some context.
• In the agricultural sector, Evogene's subsidiaries compete with companies like Bayer, Corteva, and Syngenta, which have significant resources and established market positions.
• The success of Evogene's subsidiaries will depend on their ability to develop and commercialize innovative products that can compete effectively with those offered by these larger players.
• Casterra's focus on castor seeds for biofuel places it in the renewable energy sector, where it competes with companies developing other biofuel feedstocks and technologies.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of new shares.
• The company's performance will impact employees and their job security.
• Customers of Evogene's subsidiaries will benefit from the development of new products.
• Suppliers may see increased business opportunities if Evogene's subsidiaries grow.
• Creditors face risks associated with the company's financial performance and ability to repay debts.

Next Steps

• The selling shareholder may offer and sell the ordinary shares from time to time.
• Evogene intends to use the proceeds from the exercise of warrants for research and development, working capital, investments in subsidiaries, sales and marketing, and general corporate purposes.
• Lavie Bio expects results from field trials in the fourth quarter of 2024.

Key Dates

Keywords

Evogene, ordinary shares, warrants, resale, selling shareholder, private placement, Series A warrants, Series B warrants, Securities Purchase Agreement, dilution, risk factors, Casterra, Biomica, Lavie Bio, AgPlenus